S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:TCDA

Tricida - TCDA Stock Forecast, Price & News

$13.36
-0.11 (-0.82%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.76
$13.51
50-Day Range
$8.19
$13.60
52-Week Range
$3.84
$13.79
Volume
317,270 shs
Average Volume
436,475 shs
Market Capitalization
$743.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

Tricida MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
2.3% Upside
$13.67 Price Target
Short Interest
Bearish
19.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
-0.29mentions of Tricida in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$9.52 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.20) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

1006th out of 1,116 stocks

Pharmaceutical Preparations Industry

496th out of 545 stocks

TCDA stock logo

About Tricida (NASDAQ:TCDA) Stock

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Tricida Trading Down 0.8 %

Shares of Tricida stock traded down $0.11 on Friday, reaching $13.36. The company had a trading volume of 317,270 shares, compared to its average volume of 436,475. The company has a debt-to-equity ratio of 584.92, a current ratio of 5.11 and a quick ratio of 5.11. The firm has a market cap of $743.74 million, a price-to-earnings ratio of -4.93 and a beta of 0.68. Tricida has a 1 year low of $3.84 and a 1 year high of $13.79. The firm's 50-day moving average price is $10.44 and its two-hundred day moving average price is $9.63.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group dropped their target price on shares of Tricida from $22.00 to $16.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th.

Insider Activity

In related news, major shareholder Venrock Healthcare Capital Par purchased 91,506 shares of the business's stock in a transaction dated Monday, June 6th. The shares were acquired at an average cost of $9.35 per share, for a total transaction of $855,581.10. Following the acquisition, the insider now owns 5,865,160 shares of the company's stock, valued at approximately $54,839,246. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Tricida news, major shareholder Brian M. Isern sold 37,339 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $13.42, for a total transaction of $501,089.38. Following the transaction, the insider now owns 732,675 shares in the company, valued at $9,832,498.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Venrock Healthcare Capital Par acquired 91,506 shares of the business's stock in a transaction on Monday, June 6th. The shares were purchased at an average price of $9.35 per share, with a total value of $855,581.10. Following the completion of the purchase, the insider now owns 5,865,160 shares in the company, valued at approximately $54,839,246. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 999,004 shares of company stock valued at $9,517,079. Corporate insiders own 35.60% of the company's stock.

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Stock News Headlines

Tricida (NASDAQ:TCDA) Hits New 12-Month High at $12.62
Tricida: Q2 Earnings Insights
Tricida: Q2 Earnings Insights - Benzinga
Tricida (TCDA) Scheduled to Post Earnings on Monday
Tricida, Inc. (TCDA)
Tricida - Seeking Alpha
See More Headlines
Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Company Calendar

Last Earnings
11/08/2021
Today
8/19/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCDA
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.67
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+2.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-176,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($2.00) per share

Miscellaneous

Free Float
35,851,000
Market Cap
$743.74 million
Optionable
Not Optionable
Beta
0.68

Key Executives

  • Dr. Gerrit Klaerner Ph.D. (Age 50)
    Founder, Pres, CEO & Exec. Director
    Comp: $992.55k
  • Mr. Geoffrey M. Parker (Age 57)
    COO, CFO & Exec. VP
    Comp: $656.28k
  • Mr. Robert L. McKague J.D.
    Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
  • Dr. Dawn Parsell Ph.D. (Age 60)
    Exec. VP of Clinical Devel.
    Comp: $649.17k
  • Ms. Annie Yoshiyama (Age 39)
    VP of Fin. & Chief Accounting Officer
  • Jackie Cossmon
    VP of Investor Relations & Communications
  • Mr. Edward J. Hejlek Esq. (Age 66)
    J.D., Exec. VP of Intellectual Property













TCDA Stock - Frequently Asked Questions

Should I buy or sell Tricida stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCDA shares.
View TCDA analyst ratings
or view top-rated stocks.

What is Tricida's stock price forecast for 2022?

3 analysts have issued 1-year price targets for Tricida's shares. Their TCDA share price forecasts range from $7.00 to $18.00. On average, they predict the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price.
View analysts price targets for TCDA
or view top-rated stocks among Wall Street analysts.

How have TCDA shares performed in 2022?

Tricida's stock was trading at $9.56 at the start of the year. Since then, TCDA stock has increased by 39.7% and is now trading at $13.36.
View the best growth stocks for 2022 here
.

When is Tricida's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TCDA earnings forecast
.

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.09. During the same quarter in the prior year, the firm posted ($1.55) EPS.

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by many different institutional and retail investors. Top institutional shareholders include Commodore Capital LP (3.64%), State Street Corp (0.98%), Deutsche Bank AG (0.80%), Northern Trust Corp (0.53%), Millennium Management LLC (0.40%) and Victory Capital Management Inc. (0.35%). Insiders that own company stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Kurtis R Kurimsky, Robert J Alpern, Robert Mckague, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Venrock Healthcare Capital Par and Wilhelm Stahl.
View institutional ownership trends
.

How do I buy shares of Tricida?

Shares of TCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $13.36.

How much money does Tricida make?

Tricida (NASDAQ:TCDA) has a market capitalization of $743.74 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com.

This page (NASDAQ:TCDA) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.